Formycon AG

Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences

Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®

Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA

Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard

Release of the Home Member State according to Article 5 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange

Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)

FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases

Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna

Formycon reports a strong first half-year with multiple milestones achieved

Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences

Formycon AG increases its outlook for the 2024 fiscal year

Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206

Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®

Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA

Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)

FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)

Formycon reports on the results of the Annual General Meeting

Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda